Research Article
Prognostic Analysis on Different Tumor Sizes for 14634 Hepatocellular Carcinoma Patients
Table 1
Baseline characteristics of different tumor sizes in whole cohort.
| | | Hepatocellular carcinoma-overall survival | Hepatocellular carcinoma-specific survival | | ≤2 cm | 2–5 cm | >5 cm | Overall | ≤2 cm | 2–5 cm | >5 cm | Overall | | (N = 1686) | (N = 6169) | (N = 6779) | (N = 14634) | (N = 1281) | (N = 4534) | (N = 5204) | (N = 11019) |
| | Age (years) | | 0–50 | 156 (9.3%) | 385 (6.2%) | 561 (8.3%) | 1102 (7.5%) | 137 (10.7%) | 334 (7.4%) | 500 (9.6%) | 971 (8.8%) | | 51–60 | 692 (41.0%) | 1948 (31.6%) | 1663 (24.5%) | 4303 (29.4%) | 559 (43.6%) | 1567 (34.6%) | 1426 (27.4%) | 3552 (32.2%) | | 61–70 | 576 (34.2%) | 2277 (36.9%) | 2087 (30.8%) | 4940 (33.8%) | 425 (33.2%) | 1715 (37.8%) | 1632 (31.4%) | 3772 (34.2%) | | 70+ | 262 (15.5%) | 1559 (25.3%) | 2468 (36.4%) | 4289 (29.3%) | 160 (12.5%) | 918 (20.2%) | 1646 (31.6%) | 2724 (24.7%) | | Gender | | Female | 459 (27.2%) | 1496 (24.3%) | 1483 (21.9%) | 3438 (23.5%) | 330 (25.8%) | 1069 (23.6%) | 1114 (21.4%) | 2513 (22.8%) | | Male | 1227 (72.8%) | 4673 (75.7%) | 5296 (78.1%) | 11196 (76.5%) | 951 (74.2%) | 3465 (76.4%) | 4090 (78.6%) | 8506 (77.2%) | | Race | | Black | 207 (12.3%) | 824 (13.4%) | 975 (14.4%) | 2006 (13.7%) | 159 (12.4%) | 605 (13.3%) | 761 (14.6%) | 1525 (13.8%) | | White | 1216 (72.1%) | 4296 (69.6%) | 4534 (66.9%) | 10046 (68.6%) | 917 (71.6%) | 3091 (68.2%) | 3417 (65.7%) | 7425 (67.4%) | | Others | 263 (15.6%) | 1049 (17.0%) | 1270 (18.7%) | 2582 (17.6%) | 205 (16.0%) | 838 (18.5%) | 1026 (19.7%) | 2069 (18.8%) | | Marital status | | Married | 966 (57.3%) | 3494 (56.6%) | 3740 (55.2%) | 8200 (56.0%) | 735 (57.4%) | 2587 (57.1%) | 2847 (54.7%) | 6169 (56.0%) | | Single | 720 (42.7%) | 2675 (43.4%) | 3039 (44.8%) | 6434 (44.0%) | 546 (42.6%) | 1947 (42.9%) | 2357 (45.3%) | 4850 (44.0%) | | AJCC stage | | I | 1031 (61.2%) | 3305 (53.6%) | 2116 (31.2%) | 6452 (44.1%) | 767 (59.9%) | 2364 (52.1%) | 1536 (29.5%) | 4667 (42.4%) | | II | 510 (30.2%) | 2049 (33.2%) | 381 (5.6%) | 2940 (20.1%) | 402 (31.4%) | 1533 (33.8%) | 294 (5.6%) | 2229 (20.2%) | | III | 45 (2.7%) | 226 (3.7%) | 2541 (37.5%) | 2812 (19.2%) | 37 (2.9%) | 180 (4.0%) | 1941 (37.3%) | 2158 (19.6%) | | IV | 100 (5.9%) | 589 (9.5%) | 1741 (25.7%) | 2430 (16.6%) | 75 (5.9%) | 457 (10.1%) | 1433 (27.5%) | 1965 (17.8%) | | T stage | | T1 | 1070 (63.5%) | 3486 (56.5%) | 2541 (37.5%) | 7097 (48.5%) | 797 (62.2%) | 2500 (55.1%) | 1873 (36.0%) | 5170 (46.9%) | | T2 | 550 (32.6%) | 2339 (37.9%) | 447 (6.6%) | 3336 (22.8%) | 432 (33.7%) | 1757 (38.8%) | 350 (6.7%) | 2539 (23.0%) | | T3 | 53 (3.1%) | 261 (4.2%) | 3361 (49.6%) | 3675 (25.1%) | 43 (3.4%) | 210 (4.6%) | 2628 (50.5%) | 2881 (26.1%) | | T4 | 13 (0.8%) | 83 (1.3%) | 430 (6.3%) | 526 (3.6%) | 9 (0.7%) | 67 (1.5%) | 353 (6.8%) | 429 (3.9%) | | N stage | | N0 | 1645 (97.6%) | 5913 (95.9%) | 5963 (88.0%) | 13521 (92.4%) | 1248 (97.4%) | 4337 (95.7%) | 4538 (87.2%) | 10123 (91.9%) | | N1 | 41 (2.4%) | 256 (4.1%) | 816 (12.0%) | 1113 (7.6%) | 33 (2.6%) | 197 (4.3%) | 666 (12.8%) | 896 (8.1%) | | M stage | | M0 | 1602 (95.0%) | 5735 (93.0%) | 5444 (80.3%) | 12781 (87.3%) | 1217 (95.0%) | 4190 (92.4%) | 4091 (78.6%) | 9498 (86.2%) | | M1 | 84 (5.0%) | 434 (7.0%) | 1335 (19.7%) | 1853 (12.7%) | 64 (5.0%) | 344 (7.6%) | 1113 (21.4%) | 1521 (13.8%) | | Surgery | | No/unknown | 573 (34.0%) | 2883 (46.7%) | 5047 (74.5%) | 8503 (58.1%) | 410 (32.0%) | 2032 (44.8%) | 3843 (73.8%) | 6285 (57.0%) | | Yes | 1113 (66.0%) | 3286 (53.3%) | 1732 (25.5%) | 6131 (41.9%) | 871 (68.0%) | 2502 (55.2%) | 1361 (26.2%) | 4734 (43.0%) | | Radiation | | No/unknown | 1616 (95.8%) | 5648 (91.6%) | 5940 (87.6%) | 13204 (90.2%) | 1235 (96.4%) | 4138 (91.3%) | 4551 (87.5%) | 9924 (90.1%) | | Yes | 70 (4.2%) | 521 (8.4%) | 839 (12.4%) | 1430 (9.8%) | 46 (3.6%) | 396 (8.7%) | 653 (12.5%) | 1095 (9.9%) | | Chemotherapy | | No/unknown | 1207 (71.6%) | 3693 (59.9%) | 3886 (57.3%) | 8786 (60.0%) | 898 (70.1%) | 2648 (58.4%) | 2935 (56.4%) | 6481 (58.8%) | | Yes | 479 (28.4%) | 2476 (40.1%) | 2893 (42.7%) | 5848 (40.0%) | 383 (29.9%) | 1886 (41.6%) | 2269 (43.6%) | 4538 (41.2%) | | Histology | | Hepatocellular carcinoma, clear cell type | 15 (0.9%) | 69 (1.1%) | 82 (1.2%) | 166 (1.1%) | 10 (0.8%) | 40 (0.9%) | 62 (1.2%) | 112 (1.0%) | | Hepatocellular carcinoma, fibrolamellar | 5 (0.3%) | 17 (0.3%) | 58 (0.9%) | 80 (0.5%) | 5 (0.4%) | 13 (0.3%) | 55 (1.1%) | 73 (0.7%) | | Hepatocellular carcinoma, not otherwise specified | 1662 (98.6%) | 6067 (98.3%) | 6607 (97.5%) | 14336 (98.0%) | 1264 (98.7%) | 4465 (98.5%) | 5062 (97.3%) | 10791 (97.9%) | | Hepatocellular carcinoma, scirrhous | 2 (0.1%) | 10 (0.2%) | 12 (0.2%) | 24 (0.2%) | 2 (0.2%) | 10 (0.2%) | 10 (0.2%) | 22 (0.2%) | | Hepatocellular carcinoma, spindle cell variant | 2 (0.1%) | 5 (0.1%) | 15 (0.2%) | 22 (0.2%) | 0 (0%) | 1 (0.0%) | 3 (0.1%) | 4 (0.0%) | | Hepatocellular carcinoma, pleomorphic type | 0 (0%) | 1 (0.0%) | 5 (0.1%) | 6 (0.0%) | 0 (0%) | 5 (0.1%) | 12 (0.2%) | 17 (0.2%) |
|
|
